Skip to main content

Table 3 Plasma miRNA results in MD patients vs. controls

From: Identification of cardiomyopathy associated circulating miRNA biomarkers in patients with muscular dystrophy using a complementary cardiovascular magnetic resonance and plasma profiling approach

miRNA plasma levelsa (/103) MD Controls p value
N = 63 N = 26
-206 17.20 (4.29–63.96) 0.19 (0.12–0.64) <0.0001
-144-5p 9.85 (0.00–169.32) 13.16 (6.53–19.63) 0.81
-146b 62.55 (0.00–176.97) 16.64 (6.86–33.02) 0.16
-15b 0.00 (0.00–19.61) 2.46 (0.81–3.93) 0.64
-195 9.01 (0.52–21.73) 13.63 (10.46–16.81) 0.053
-20b 61.74 (21.70–85.10) 35.95 (27.39–51.02) 0.048
-21 30.61 (0.00–110.97) 9.58 (5.86–18.33) 0.48
-221 0.00 (0.00–20.44) 10.61 (7.73–17.12) 0.001
-222 1923.17 (881.56–5111.93) 79.22 (43.34–169.52) <0.0001
-26a 293.34 (121.00–554.69) 49.40 (26.58–63.10) <0.0001
-29a 0.00 (0.00–0.00) 0.07 (0.00–1.11) 0.002
-29c 0.00 (0.00–1.43) 0.56 (0.27–2.72) 0.001
-342 2427.02 (1198.59–4185.82) 73.89 (45.30–171.19) <0.0001
-378a-3p 30 (5.07–268.79) 0.00 (0.00–0.23) <0.0001
-378a-5p 27.57 (8.84–81.04) 0.58 (0.30–1.79) <0.0001
-451 184.13 (73.28–343.07) 144.45 (107.74–169.24) 0.19
-93 26.82 (0.00–66.29) 35.37 (25.60–49.70) 0.24
  1. (a) – Each miRNA plasma level was normalized to miR-16 plasma levels and thereafter multiplied by 103 in order to increase readability
  2. Bold text indicates a significant p-value of <0.05